GlobalData on MSN8d
FDA grants breakthrough designation for Acrivon’s endometrial cancer assayThe US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...
Hosted on MSN4h
Blood Test for Early Pancreatic Cancer Shows PromiseHe noted that other assays studied in pancreatic cancer have only examined a handful of samples. "When they publish a second ...
The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...
Myriad continues to develop its Precise MRD assay to meet the needs of patients with cancer, academic partners, and biopharma ...
A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the ...
Credit: Thinkstock Investigators explored the potential of a noninvasive ctDNA assay as a predictive biomarker for advanced or metastatic urothelial cancer. Increases in circulating tumor DNA ...
WATERTOWN, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage ...
Medpage Today on MSN7h
What's the Better Option for High-Risk Prostate Cancer -- Radiation or Surgery?SAN FRANCISCO -- Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when ...
The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection.Golden, CO, Feb. 10, 2025 (GLOBE ...
A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback